Literature DB >> 7727831

Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism.

B A Salzer1, K U Schallreuter.   

Abstract

BACKGROUND: Patients with vitiligo show an increased beta 2-adrenoceptor density in differentiating vitiliginous keratinocytes correlating with a defective extracellular calcium uptake. Thirty-one percent of the patients present increased norepinephrine levels in their urine and 98% in their plasma.
OBJECTIVE: The aim of this study was to find out whether these patients may: (a) have a characteristic personality structure and/or (b) show an increased stress sensitivity towards physical/environmental/hormonal changes in association with a defective catecholamine metabolism. METHODS AND
RESULTS: The investigation included a randomized group of 117 patients with vitiligo (89 female, 28 male). Catecholamines were determined in plasma in a random sample of the total group (n = 30, M/F = 10/20). Norepinephrine levels in plasma were significantly higher compared to controls, whereas epinephrine was within the normal range. No specific personality pattern was found although divergencies from the normal healthy control were observed in 5 out of 12 personality dimensions. Moderate to intolerable disfigurement and psychological disturbance were stated by 75% of the patients. Evaluation of the educational status revealed that 26.5% of the patients graduated successfully from university compared to 8.4% in the normal population.
CONCLUSION: The results of this study suggest a possible link between catecholamine-based stress and a genetic susceptibility to the onset/progression of this depigmentation disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7727831     DOI: 10.1159/000246657

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  17 in total

Review 1.  Beta adrenergic receptors in keratinocytes.

Authors:  Raja K Sivamani; Susanne T Lam; R Rivkah Isseroff
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

2.  [Vitiligo. What is new?].

Authors:  K U Schallreuter; M M A E L Salem
Journal:  Hautarzt       Date:  2010-07       Impact factor: 0.751

Review 3.  New treatment modalities for vitiligo: focus on topical immunomodulators.

Authors:  Kresimir Kostovic; Aida Pasic
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Defective calcium transport in vitiliginous melanocytes.

Authors:  K U Schallreuter-Wood; M R Pittelkow; N N Swanson
Journal:  Arch Dermatol Res       Date:  1996       Impact factor: 3.017

5.  Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study.

Authors:  A Ruiz-Argüelles; M García-Carrasco; G Jimenez-Brito; S Sánchez-Sosa; B Pérez-Romano; J Garcés-Eisele; C Camacho-Alarcón; V Reyes-Núñez; M Sandoval-Cruz; C Mendoza-Pinto; A López-Colombo
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

6.  Psychodermatology: a guide to understanding common psychocutaneous disorders.

Authors:  Mohammad Jafferany
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

7.  Relevance of psychiatry in dermatology: Present concepts.

Authors:  K H Basavaraj; M A Navya; R Rashmi
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

8.  Dermatology life quality index scores in vitiligo: reliability and validity of the Tunisian version.

Authors:  Akrem Jalel; Gaigi Siala Soumaya; Mohamed Hédi Hamdaoui
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

Review 9.  Quality of life in patients with vitiligo.

Authors:  Davinder Parsad; Sunil Dogra; Amrinder Jit Kanwar
Journal:  Health Qual Life Outcomes       Date:  2003-10-23       Impact factor: 3.186

10.  DLQI scores in vitiligo: reliability and validity of the Persian version.

Authors:  Shahin Aghaei; Manouchehr Sodaifi; Peyman Jafari; Nazila Mazharinia; Andrew Y Finlay
Journal:  BMC Dermatol       Date:  2004-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.